CAMBRIDGE, Mass., April 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that members of its scientific teams will be reporting preclinical data from its novel Hedgehog pathway inhibitor program -- an emerging area of cancer research -- during the 2010 American Association of Cancer Research (AACR) Annual Meeting being held in Washington, D.C. from April 17 through April 21, 2010. Infinity’s novel Hedgehog pathway inhibitor, IPI-926, is a potent, orally delivered small molecule drug candidate that has demonstrated significant anti-tumor activity in multiple preclinical cancer models. IPI-926 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors.
